T2 Biosystems, Inc. (NASDAQ:TTOO) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET
Company Participants
Philip Taylor - IR, Gilmartin Group
John Sperzel - Chairman & CEO
John Sprague - CFO
Conference Call Participants
Kyle Mikson - Canaccord
Operator
Greetings. Welcome to the T2 Biosystems, Inc. First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.
I will now turn the conference over to your host, Philip Taylor. You may begin.
Philip Taylor
Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems' future financial and operating results and plans for developing and marketing new products. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these statements, including the risks and uncertainties described in T2 Biosystems' annual report on Form 10-K filed with the SEC on April 1, 2024, and other filings the company makes with the SEC from time to time. The company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
With that, I would like to turn the call over to Chairman and CEO, John Sperzel. John?
John Sperzel
Thank you for joining our first quarter 2024 results call. I will start with an update on our NASDAQ compliance plan and our capital plans and then discuss our first quarter progress across our three corporate priorities. Before turning the call over to John Sprague, our Chief Financial Officer, who will review our financial results and outlook for 2024. I will then provide closing remarks and open the call for questions and answers.
On March 12, 2024, we announced that the NASDAQ Hearings Panel had granted our request for continued listing on the NASDAQ stock market, subject to the company demonstrating compliance with NASDAQ's market value of listed securities or market value requirement as set forth in NASDAQ Listing rule 5550(b)(2) the rule on or before May 20, 2024. The rule requires that the company maintain a closing market value of at least $35 million for a minimum of 10 consecutive business days.